Emblation announced that Swift®, the breakthrough microwave treatment system, is now available in the U.S. The Swift® system is a surface-based device intended for the coagulation of soft tissue during non-invasive procedures, and received 510(k) clearance in October 2018.

Saorsa Inc, based in Seattle, Wash., is the exclusive partner for Swift® in the U.S., and the first system was delivered to Temple University School of Podiatric Medicine in Philadelphia, Penn.

Emblation CEO Gary Beale and Saorsa co-founder, Pete Turnbull, both travelled to Philadelphia to visit with Dr Tracey Vlahovic and witness the first U.S. treatments to take place.

Emblation CEO, Gary Beale, commented: "With the success we’ve seen in the U.K., Canada and Australia, we’re excited to finally deliver Swift to the U.S. Our commercial partners Saorsa have already been working hard delivering training to a number of new treatment sites across the country, and we look forward to hearing more stories from patients who have benefited from the fantastic results Swift provides.”

With treatment times in seconds, Swift® delivers a fast, simple, clean and effective option for skin lesions. Low level microwave energy (compared to existing microwave systems) is delivered with precision into the skin to a predetermined depth via a surface-contact probe, delivering rapid internal heat generation with minimal damage to the skin surface. The Swift® microwave system has been used in more than 30,000 procedures across the U.K., Canada and Australia and is now available in North America.